Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Seeks Global Resolution Of Opioid Litigation

Bellwether Trial In US Is Halted By Settlement Agreement

Executive Summary

Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework.

You may also be interested in...



Zydus Ready For Moraiya Reinspection In June

Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.

Teva On Track To Hit Targets With Truxima

Teva says it is on track to achieve both its sales targets and its restructuring goals as it prepares to enjoy the benefits of being first to market with a rituximab biosimilar in the US.

Opioid Trial Preview: The Claims, Defenses, And Last-Minute Maneuvers

Trial opens after settlement proposals by three distributors, Teva and J&J fail to gain support of cities and counties. Distributors want to call former FDA Commissioner Kessler to testify over plaintiffs' objections. Judge rules plaintiffs cannot seek future damages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149282

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel